Last year BETonMACE, the first clinical trial investigating BET inhibitors in patients with recent acute coronary syndrome and type 2 diabetes, failed to show a benefit of BET inhibition for cardiovascular death, nonfatal myocardial infarction, or stroke as primary outcome.3 However, further analysis of the data was published this year and revealed that BET inhibition was associated with fewer hospitalizations for heart failure in patients with type 2 diabetes and recent acute coronary syndrome.3 BET inhibitors broadly affect several cell types throughout the body. The gene discussed is DNER; the disease is type 2 diabetes mellitus.